Review

Current progress in the derivation and therapeutic application of neural stem cells

Yuewen Tang1, Pei Yu2 and Lin Cheng*1

Neural stem cells (NSCs) have a unique role in neural regeneration. Cell therapy based on NSC transplantation is a promising tool for the treatment of nervous system diseases. However, there are still many issues and controversies associated with the derivation and therapeutic application of these cells. In this review, we summarize the different sources of NSCs and their derivation methods, including direct isolation from primary tissues, differentiation from pluripotent stem cells and transdifferentiation from somatic cells. We also review the current progress in NSC implantation for the treatment of various neural defects and injuries in animal models and clinical trials. Finally, we discuss potential optimization strategies for NSC derivation and propose urgent challenges to the clinical translation of NSC-based therapies in the near future.

Cell Death and Disease (2017) 8, e3108; doi:10.1038/cddis.2017.504; published online 12 October 2017

Facts

- NSCs are a promising treatment modality for diseases associated with the nervous system as they secrete soluble factors and differentiate into neurons, astrocytes and oligodendrocytes.
- NSCs can be derived from three different sources using recent technical advances: direct isolation from primary tissues, differentiation from pluripotent stem cells and transdifferentiation from somatic cells.
- Cell therapies based on NSC transplantation for the treatment of various neural defects and injuries in animal models and clinical trials have been widely investigated.

Open Questions

- Which NSC derivation strategy is most efficient and safe for clinical translation?
- How can NSC transplantation methods be translated from preclinical studies into clinical trials?
- What are the optimization strategies and urgent challenges for the clinical translation of NSC-based therapies in the near future?

Nervous system diseases are refractory diseases that can cause loss of sensation, loss of motor function and memory failure, as well as directly threaten the life of a patient. Currently, the pathogenic factors involved in these diseases and their pathogenesis are unclear. Traditional drug treatments are used to delay disease progression and cannot restore function or regenerate tissues. Recent studies have indicated that the transplantation of neural stem cells (NSCs) is a promising treatment modality for diseases associated with the nervous system, for the regeneration of neural cells and for the restoration of the microenvironment at the injury site (Figure 1).

The cell source is the first issue that must be addressed to enable the application of NSCs in clinical treatments because the cell dose required for adequate transplantation is very high. NSCs can be derived from three different sources using recent technical advances, including direct extraction from primary tissues, differentiation from pluripotent stem cells and transdifferentiation from somatic cells (Figure 2 and Table 1).

Strategies for the Isolation and Generation of NSCs

Isolating and culturing NSCs from primary tissues. The establishment of cell isolation and cell culture techniques has led to the development of favorable experimental methods and the identification of a rich cell source for NSC research. In 1992, Reynolds and Weiss isolated NSCs from the striatum of the adult mouse brain and reported the first use of epidermal growth factor (EGF) to induce NSC proliferation in vitro.1 Two years later, they found that the subependymal region in the mouse brain is the source of NSCs in vivo.2 Based on previous results, Weiss further reported that EGF and basic fibroblast growth factor (bFGF) cooperatively induce the proliferation, self-renewal and expansion of NSCs
isolated from adult mouse thoracic spinal cord. NSCs can grow in single-cell suspensions obtained by enzymatic digestion and form spherical clusters called neurospheres, which are non-adherent and can be re-plated in selective culture medium to obtain neural cells. Periventricular regions and olfactory bulb in adult mammalian brains are rich sources of NSCs. Beyond these methods of isolating NSCs through diverse culturing strategies, NSCs can also be directly isolated by cell sorting based on the expression of NSC surface markers. Belenguer and Guo have developed an optimized protocol for the isolation, culture and expansion of NSCs from mammalian animals. Although, a canonical
Isolation from primary tissues

ESC and iPSC colonies are detached and grow in suspension to form EBs. Subsequently, EBs are plated on adhesive substrates with defined serum-free medium that promote the generation of neural tube-like rosettes and the selection of neural progenitor cells (NPCs). 

Differentiation from pluripotent stem cells into NSCs. Pluripotent stem cells, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), can generate desired cells through differentiation, which are attractive alternatives to primary cell isolation. Generally, protocols for neural differentiation from pluripotent stem cells can be categorized into two major routes: embryoid body (EB) formation and monolayer culture.

In the protocol for EB formation, ESC and iPSC colonies are detached and grow in suspension to form EBs. Subsequently, EBs are plated on adhesive substrates with defined serum-free medium that promote the generation of neural tube-like rosettes and the selection of neural progenitor cells (NPCs). Zhang et al. first described the differentiation, enrichment and transplantation of neural precursor cells from human ESC-derived EBs in vitro. Later, Kozhich et al. developed a novel protocol suitable for standardized generation and differentiation of neural precursor cells from human pluripotent stem cells, making iPSC-derived NSCs an appealing source for cell-based therapies. Pluripotent stem cells can also directly differentiate into NSCs in monolayer culture via the neural rosettes stage, which is a striking feature here. A serum-free and nutrient-poor medium is utilized to initiate differentiation, and depending on the cell line, additional growth factors or inhibitors may be required to promote neural differentiation. Banda and Grabel have been focusing on using monolayer culture to directly differentiate human ESCs into neural progenitors, which includes four typical stages. Wen and Jin have developed a straightforward and useful protocol for obtaining human tissue-derived NSCs has not yet been established, the technical methods are generally similar to the ones applied in animals, and the tissues must be obtained in accordance with ethical guidelines.

### Table 1: Derivation of neural stem cells

| Species          | Original tissues/cells | Treatment                                      | Duration to derive NSCs | Refs |
|------------------|------------------------|------------------------------------------------|-------------------------|------|
| Mouse            | Striatum               | EGF                                            | 1 week                  | 1    |
| Mouse            | Thoracic spinal cord   | EGF, bFGF                                      | 1 week                  | 3    |
| Mouse            | Dentate gyrus, SVZ     | EGF, bFGF                                      | 1–3 weeks               | 4,10,11 |
| Mouse            | Periventricular region | EGF, bFGF, heparin                             | 2 weeks                 | 5    |
| Mouse            | Olfactory bulb         | EGF, bFGF                                      | 2–3 weeks               | 6    |
| Mouse            | Olfactory bulb         | EGF, bFGF                                      | 1–2 weeks               | 7    |
| Mouse            | Postnatal cerebellum   | EGF, bFGF                                      | 1–2 weeks               | 8    |
| Human            | ESCs                   | Suspension culture                             | 3–4 weeks               | 13   |
| Human            | ESCs                   | Adhesion co-culture with stromal cells MS-5     | 3 weeks                 | 18   |
| Human            | ESCs                   | Adherent monolayer culture                     | 3–5 weeks               | 20   |
| Human            | iPSCs                  | Suspension and adherent culture                | 2–5 weeks               | 21   |

| Species          | Original tissues/cells | Treatment                                      | Duration to derive NSCs | Refs |
|------------------|------------------------|------------------------------------------------|-------------------------|------|
| Mouse            | Fibroblasts            | Oct4, Sox2, Klf4, c-Myc                         | 2–3 weeks               | 24,25|
| Mouse            | Fibroblasts            | Brn4/Pou3f4, Sox2, Klf4, c-Myc, E47/Tcf3         | 4–5 weeks               | 26   |
| Mouse            | Fibroblasts            | Foxg1, Sox2, Bm2                                | 3–4 weeks               | 27   |
| Human            | Fibroblasts            | Sox2                                            | 2–3 weeks               | 28   |
| Human            | Fibroblasts            | ZFP521                                          | 3–4 weeks               | 29   |
| Human            | Primates               | OCT4, SOX2, KLF4, c-MYC, SB431542, CHIR99021    | 2–3 weeks               | 30   |
| Human            | Fibroblasts            | OCT4, A83-01, CHIR98021, NaB, LPA, Rolipram, SP600125 | 4 weeks                | 31   |
| Human            | Sertoli cells          | Ascl1, Ngn2, Hes1, Id1, Pax6, Brn2, Sox2, c-Myc, Klf4 | 4–5 weeks               | 32   |
| Mouse            | Liver cells and B cells| Brn2, Hes1, Hes3, Klf4, c-Myc, Notch1, PLAGL1, Rbx4 | 4–5 weeks               | 33   |
| Human            | Urine cells            | SOX2, KLF4, c-MYC, SV40LT, miR302-367, A83-01, PD0325901, CHIR99021, Thiazovivin, DMH1 | 4–5 weeks               | 34   |
| Human            | Astrocytes             | OCT4, SOX2, NANOG                               | 2–3 weeks               | 35   |
| Human            | Cord blood CD34+ cells | OCT4, CHIR99021, Repsox                        | 2–3 weeks               | 36   |
| Human            | Fibroblasts, urine cells| VPA, CHIR99021, Repsox                        | 3 weeks                 | 37   |
| Mouse            | Fibroblasts            | CHIR99021, LDN193189, A83-01, Hh-Ag1.5, Vc, SMER28, RG108, Parnate | 2 weeks                | 38   |
| Mouse            | Fibroblasts            | VPA, Forskolin, Tranylcypromine, CHIR99021, Repsox, SB431542, Dorosomorphin | 2 weeks                | 39   |
| Mouse            | Fibroblasts            | VPA, A83-01, Purmorphamine, Vc, NaB, Thiazovivin | 2 weeks                | 40   |
| Mouse            | MSCs                   | bFGF, EGF                                      | 1–2 weeks               | 42,43|
| Human            | Fibroblasts            | bFGF, EGF, heparin, LIF                         | 3–4 weeks               | 45   |
| Mouse            | Fibroblasts            | 3D sphere culture                              | NA                      | 46   |

Abbreviations: bFGF, basic fibroblast growth factor; 3D, three dimension; EGF, epidermal growth factor; ESCs, embryonic stem cells; iPSCs, induced pluripotent stem cells; LIF, leukemia inhibitory factor; LPA, lysophosphatidic acid; MSCs, mesenchymal stem cells; NA, not available; NaB, sodium butyrate; SVZ, subventricular zone; Vc, ascorbic acid; VPA, valproic acid

---

{Cell Death and Disease}
strategy for the generation of NSCs from both human ESC and iPSC lines. Comparisons of NSC marker expression and morphology have indicated that there are no significant differences between the NSCs derived via EB formation and monolayer culture methods.

Transdifferentiation of somatic cells into NSCs. The term transdifferentiation, also known as lineage reprogramming, was originally coined by Selman and Kafatos in 1974. During this process, one type of mature somatic cell transforms into another type of mature somatic cell without undergoing an intermediate pluripotent state. This process is induced mainly by the exogenous expression of lineage-specific transcription factors (TFs) and by chemical compounds.

TF-induced transdifferentiation. Ding and others first demonstrated that transient expression of pluripotency factors combined with the appropriate neural signaling inputs can successfully induce mouse fibroblasts to form expandable NSCs, which can successfully induce mouse fibroblasts to form expandable NSCs from both primate and human fibroblasts, thus suggesting that small-molecule chemically induced expansion of NSCs, which were called induced NSCs (iNSCs). This finding provides a new strategy for the generation of NSCs through direct cell transdifferentiation following virus-mediated exogenous gene expression. Aside from the pluripotency factors, NSC-specific TFs can also induce the generation of neural stem-like cells with self-renewal and tripotent differentiation potential. Furthermore, it is found that a single TF, Sox2 or ZFP521, can be used to generate iNSCs from mouse and human fibroblasts. Two Chinese teams, led by Zhang and Ding, have separately combined defined TFs with chemical cocktails that enable the generation of expandable iNSCs from both primate and human fibroblasts, thus suggesting that small-molecule chemicals can increase the efficiency of iNSC generation. In addition to fibroblasts, many other somatic cell types are considered to be ideal starting cells for NSC generation depending on the clinical situation, including Sertoli cells, adult liver cells and B lymphocytes, urine epithelial-like cells, astrocytes, and cord blood sample.

Chemical compound-induced transdifferentiation. In recent years, researchers have explored chemical reprogramming as a new method to manipulate cell fate. Compared with the conventional practice of importing exogenous viral genes to induce cell transdifferentiation, the use of small-molecule chemicals to elicit cell transdifferentiation has many obvious advantages in terms of safety and controllability.

We were the first to report using only a chemical cocktail containing valproic acid (VPA), CHIR99021 and Repsox, which inhibits histone deacetylases (HDACs), glycogen synthase kinase (GSK)-3 and transforming growth factor (TGF)-β, respectively, to generate chemically induced NPCs (ciNPCs) from mouse embryonic fibroblasts under hypoxic conditions. Further assays confirmed that mouse tail-tip fibroblasts and human urinary cells can also be induced into ciNPCs via treatment with the same chemical cocktail. This work demonstrates that direct lineage-specific conversion to NPCs can be achieved without introducing exogenous genes and that physiological hypoxia is essential for the initial transition process. In the absence of hypoxic conditions, Zhang et al. developed a cocktail of eight small-molecule components, namely CHIR99021, LDN193189 (an inhibitor of the BMP type I receptor ALK2/3), A83-01 (an inhibitor of the TGF-β type I receptor ALK4/5/7), Hh-Ag1.5 (a potent smoothened agonist), RA, SMER28 (an autophagy modulator), RG108 (a DNA methyltransferase inhibitor) and Parnate (a histone demethylase inhibitor), which can efficiently and specifically transdifferentiate mouse fibroblasts into NSC-like cells. These cells resemble primary NSCs in terms of their long-term self-renewal and tripotent differentiation abilities. Takayama et al. also developed a small-molecule cocktail composed of VPA, Forskolin (an adenylyl cyclase activator), Repsox, CHIR99021, Repsox, Dorosomorphin (a selective inhibitor of BMP signaling) and SB431542 (a selective inhibitor of TGF-β receptor I, such as ALK4 and ALK7) to induce neural crest-like precursors from mouse embryonic fibroblasts. Zheng et al. showed that a combination of A83-01, Purmorphamine (a smoothened receptor agonist), VPA and Thiazovivin (a selective Rho-associated protein kinase inhibitor) can directly lead to the generation of ciNPCs. Despite these achievements, the mechanisms underlying chemically induced transdifferentiation remain largely unknown. Global gene expression profiles determined through microarray analysis have revealed that the small-molecule-based culture method strongly affects cell identity and specifically induces neural differentiation and development-related genes. Interestingly, small molecules targeting HDACs, GSK-3 and TGF-β are included in most of the abovementioned reports and may constitute the core chemicals. It can be speculated that HDAC inhibitors cause chromatin decondensation and induce cells into a plastic state. TGF-β inhibitors may regulate cell transition between the mesenchymal and epithelial states and promote cell fate conversion, and GSK-3 inhibitors probably activate Wnt signaling, which helps maintain stem cell properties.

Growth factor or three-dimensional culture-induced transdifferentiation. Regardless of the method used for NSC derivation, growth factors are utilized, which indicate the significance of these factors. Without the introduction of any exogenous genes and chemicals, Feng et al. successfully established a three-step induction protocol that generates highly purified neural stem-like cells from human adipose-derived mesenchymal stem cells (MSCs) by activating SOX1 with conditional medium, EGF and bFGF. In addition, Song and Sanchez-Ramos proposed a detailed protocol with which to generate neural-like progenitors from bone marrow-derived MSCs and umbilical cord blood-derived MSCs. Later, Ge et al. found that cerebrospinal fluid containing growth factors may be a better microenvironment for a more rapid transition of MSCs to a NSC fate. Recently, Gao et al. reported a method for neural precursor cell generation from mouse fibroblasts using physical stress and a few growth factors, including EGF, bFGF, leukemia inhibitory factor and heparin, which synergize to regulate the signaling pathways upstream and downstream of Sox2. During this direct induction process, cells first pass through a transient partially reprogrammed state, and then, cell transdifferentiation is achieved via a safe, non-integrated and efficient method.
Given that stem cells reside in specific niches in vivo, a three-dimensional in vitro culture system should mimic the complex physical environment and enhance NSC self-renewal and multipotency compared with traditional two-dimensional culture conditions. Su et al.\textsuperscript{46} reported that mouse fibroblasts can be converted into three-dimensional spheres on non-adherent substrates and later exhibit the characteristics of neural progenitor-like cells in terms of cell morphology, specific marker expression and self-renewal ability. Immuno-cytotoxicity experiments have indicated that the expression of Sox2 is significantly upregulated in three-dimensional cultured mouse fibroblasts. This study has introduced a new paradigm for safer and more convenient cell transdifferentiation using physical tools. This study suggests that other three-dimensional scaffolds might also be used during inNSC generation. For example, graphene foam, a three-dimensional porous scaffold that is biocompatible and conducive to NSC proliferation, has shown great potential for NSC research, neural tissue engineering and neural prostheses.\textsuperscript{37}

**Progress in NSC Transplantation for the Treatment of Diseases**

**Neurodegenerative diseases.** Neurodegenerative diseases are caused by neural or glial cell defects in the brain or spinal cord, which lead to memory deterioration, cognitive disorders, dementia or body movement disorders and mainly include amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), Alzheimer’s disease (AD) and Huntington’s disease (HD).

ALS is characterized by degeneration and loss of motor neurons in the cerebral cortex, brain stem and spinal cord, thus resulting in muscle wasting, weakness and, eventually, death within 5 years.\textsuperscript{46} Human NSCs secrete glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor, which induced the regeneration of motor neurons in a transgenic rat model of ALS.\textsuperscript{48} Besides, human iPSCs-derived NSCs effectively improve the function of neuromuscular and motor units and significantly increase the lifespan of ALS mice after intrathecal or intravenous injection.\textsuperscript{50} Beyond the animal models, NSC treatment for ALS has been at the clinical trial stage for years. The clinical results indicate the safety of this therapeutic approach via spinal cord injection.\textsuperscript{51–53}

PD is a disease characterized by the loss of dopamine neurons in the substantia nigra pars compacta and their terminals in the striatum.\textsuperscript{54} In toxin-induced animal models of PD, transplanted human NSCs stimulate the dedifferentiation of rat astrocytes and the secretion of exogenous growth factors, thus inhibiting the activation of microglial cells and slowing PD progression by modulating the lesion microenvironment.\textsuperscript{55,56} As Lmx1a contributes to NSC differentiation into dopamine neurons, the transplantation of Lmx1a-overexpressing iNSCs markedly enhances the efficiency of dopamine neuron production and elicits therapeutic effects in a PD mouse model.\textsuperscript{57} Although NSC transplantation in PD animal models has shown a certain degree of benefit,\textsuperscript{58–61} additional studies are required to elucidate its clinical efficacy and safety. To date, one report has verified that human parthenogenetic stem cell-derived NSCs (hpNSCs) can successfully engraft, survive long-term and increase dopamine levels in the brains of rodent and nonhuman primate models of PD. In addition, hpNSCs have negligible tumorigenic potential and are safe for clinical application, thus supporting the approval of an hpNSC-based phase I/IIa study for the treatment of PD.\textsuperscript{62,63}

AD is characterized by increased levels of both soluble and insoluble amyloid beta peptides.\textsuperscript{64} It has also been reported that hippocampal neuronal mitochondria levels are decreased in AD patients. Transplantation of exogenous NSCs into transgenic AD mice leads to a significant increase in the number of mitochondria and the expression of mitochondria-related proteins, as well as improvements in mouse cognitive function.\textsuperscript{65} The therapeutic effect of NSC transplantation can be further improved by combining with cerebrolysin controlling amyloid precursor protein metabolism,\textsuperscript{66} self-assembled peptides providing a protective niche\textsuperscript{67} and nerve growth factor nanoparticles.\textsuperscript{68} Human NSCs have also been intensively investigated as an AD treatment in transgenic animal models\textsuperscript{69,70}. Although many positive results have been reported based on those models, there were still negative consequences emerged. Marsh et al.\textsuperscript{71} used an immunodeficient AD model to examine the long-term effects of the transplantation of human NSC products and found that five months after transplantation, human NSCs had engrafted and migrated throughout the hippocampus; however, changes in brain-derived neurotrophic factor expression and increases in synaptic density were not observed. The disappointing result of this assay might be due to the failure of the human NSCs to terminally differentiate, which reinforces the notion that candidate cells need to be thoroughly evaluated for safety and efficacy before every transplantation. Considering these inconsistent data, to date, there have been no clinical study of NSC transplantation in AD patient.

HD is an autosomal-dominant inherited disease that induces caudate nucleus atrophy and is characterized by involuntary choreic movements, cognitive impairment and emotional disturbance.\textsuperscript{72} Animal HD models can be established by injecting quinolinic acid into rodent and primate striatum to simulate excitotoxicity. Human fetal NSCs can differentiate into neurons and astrocytes following transplantation into the rat striatum, partially eliciting behavioral and anatomical recovery in HD rats.\textsuperscript{73} Furthermore, intracerebral transplantation of NSCs combined with trehalose has been found to not only alleviate polyglutamine aggregation formation and decrease striatal volume but also extend lifespan in transgenic mouse model of HD.\textsuperscript{74} To further promote the beneficial effects of transplanting NSCs in animal models of HD, the timing of transplantation and cell preparation, NSC activity and co-transplantation of NSCs with helper cells, such as MSCs that secrete brain-derived neurotrophic factor, need to be fully considered based on the pathological conditions.\textsuperscript{75,76}

**Spinal cord injury.** Spinal cord injury (SCI) is a severe physical injury and often gives rise to severe loss of motor function and secondary damage.\textsuperscript{77} There are no effective conventional treatments for SCI, but transplantation of NSCs in a mouse model of SCI leads to significant improvements in...
motor function recovery, thus indicating that NSCs can survive in vivo, differentiate, and alter the microenvironment of early chronic injury sites. In a primate SCI model, transplanted NSCs have been found to differentiate into cells expressing neuronal markers, thereby improving hind limb performance. Considering that treatment of SCI with NSCs is regulated by a variety of cytokines and proteins, drugs that modulate these factors will be a helpful adjunctive therapy, such as etanercept having anti-inflammatory and anti-apoptotic effects, free radical scavenger edaravone, and erythropoietin. With the rapid development of tissue engineering techniques, biomaterials have gradually been applied to SCI treatment and have provided new prospects for NSC transplantation; for example, biodegradable scaffolds with aligned columns and gelatine sponge scaffold. In contrast to these positive results, Anderson et al. found that human CNS-derived stem cells failed to show preclinical efficacy in a pathway study of cervical SCI. In that study, no evidence of donor cell differentiation into the neuronal lineage was observed. This failure might be attributed to the insufficient characterization of the clinical cell line supplied by the sponsor using potency assays. However, in a phase I/IIa clinical trial on the transplantation of fetal cerebral NSCs into 19 traumatic cervical SCI patients, 17 patients regained sensorimotor function after 1 year, and 2 patients showed complete motor but incomplete sensory recovery. There was no evidence of cord damage; syrinx or tumor formation; neurological deterioration; and exacerbating neuropathic pain or spasticity.

**Stroke.** Stroke is an acute cerebrovascular disease that includes ischemic and hemorrhagic stroke. Transplanted mouse iPSC-derived or human fetus-derived NSC lines have been reported to provide neurotrophic factors and increase angiogenesis and neurogenesis in both ischemic and hemorrhagic stroke animal models. Besides, Li et al. demonstrated that compared with transplantation of NPC alone, co-transplantation with vascular progenitor cells, which might support NPC survival, leads to more effective improvements in neurovascular recovery and attenuation of the infarct volume. Furthermore, the application of three-dimensional electrospun fibers as cell carriers has shown promising results and has been found to extend the survival rate of administered human NSCs by blocking microglial infiltration in an animal model of stroke induced by middle cerebral artery occlusion. Despite positive results from animal assays, caution should be exercised before clinical trials, because other findings have suggested that endogenous neurogenesis is decreased after NPC treatment via microglial activation. However, in pioneering work, the United Kingdom has already initiated phase I/II clinical trials on the treatment of ischemic stroke with CTX00603, an immortalized human NSC line. Thirteen men were recruited for the phase I trial in which a single dose of up to 20 million cells was implanted via stereotactic ipsilateral putamen injection, and whereas neurological function was improved, no adverse events were observed. Based on the results of the phase I trial, the phase II trial was initiated and is still underway.

**Traumatic brain injury.** The principal mechanisms of traumatic brain injury (TBI) are classified as focal brain damage and diffuse brain damage, which correspond to contact injury and acceleration/deceleration injury types. TBI is extremely likely to cause cognitive and memory deficits as well as motor impairments. Previous study concluded that NSCs may stabilize the cortical microenvironment after TBI. Transplantation of mouse brain-derived NSCs into brain injury mice effectively prevents astrogial activation and microglial/macroglial accumulation while increasing oligodendrocytes and repairing and maintaining normal neuron function. A sodium hyaluronate collagen scaffold loaded with bFGF promotes the survival and differentiation of transplanted rat NSCs and promotes functional synapse formation to repair traumatic brain injuries in rats. In a clinical study, Zhu's group labeled autologous cultured NSCs with superparamagnetic iron oxide nanoparticles and then stereotactically implanted them around the regions of brain trauma in TBI patients. Magnetic resonance imaging tracking images showed the accumulation and proliferation of cells around the lesion and even their migration from the primary sites of injection to the border of the damaged tissue.

**Epilepsy.** Epilepsy is an abnormal discharge of cerebral neurons resulting from an imbalance between excitation and inhibition in the CNS; this imbalance leads to transient cerebral dysfunction, which is mainly related to changes in ion channel neurotransmitters and glial cells. Nearly 30% of patients with temporal lobe epilepsy (TLE) are resistant to antiepileptic drugs. Current reports demonstrate that NSC transplantation can inhibit spontaneous seizures. When transplanted into the epileptic sites of the hippocampus, exogenous NSCs produce a specific type of neuron that synthesizes the inhibitory neurotransmitter γ-aminobutyric acid and astrocytes that secrete anticonvulsant factors, which slow the cognitive and emotional dysfunction caused by TLE.

**Cerebral palsy.** Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood, which is due to the formation of non-progressive lesions in the developing central nervous system. At present, CP treatment includes many measures, but none of these treatments can cure CP patients. In recent years, the safety and efficacy of NSC/NPC therapy for CP has been evaluated. Based on current studies, transplantation of NSCs transduced with vascular endothelial growth factor can partially treat CP patients with temporal lobe epilepsy (TLE) are resistant to antiepileptic drugs. Current reports demonstrate that NSC transplantation can inhibit spontaneous seizures. When transplanted into the epileptic sites of the hippocampus, exogenous NSCs produce a specific type of neuron that synthesizes the inhibitory neurotransmitter γ-aminobutyric acid and astrocytes that secrete anticonvulsant factors, which slow the cognitive and emotional dysfunction caused by TLE.
| Disease target | Animal model | Transplanted cell source | Therapeutic mechanism | Outcome |
|----------------|--------------|--------------------------|-----------------------|---------|
| ALS SOD1 (G93A) transgenic rat | Human fetal spinal cord-derived NSCs | Increased glial cell line-derived and brain-derived neurotrophic factors | Improved motor function and extended lifespan |
| ALS SOD1 (G93A) transgenic mouse | Human iPSCs-derived NSCs | Increased neurotrophic factors and enhanced gliosis | Improved neuromuscular function and extended lifespan |
| PD 6-OHDA-induced mouse | NSCs transdifferentiated from mouse serotini cells with Lmx1a | Enhanced tyrosine hydroxylase signal and increased endogenous dopaminergic neurons | Improved motor function |
| PD MPTP-induced monkey | Human parthenogenetic stem cell-derived NSCs | Enhanced striatal dopamine concentration, fiber innervation and number of dopaminergic neurons | Promoted behavior recovery |
| AD APP/PS1 transgenic mouse | Mouse fetal brain-derived NSCs | Enhanced mitochondria biogenesis | Decreased cognitive deficits |
| AD APP transgenic mouse | Mouse cortical NSCs with cerebrolysin | Increased survival of grafted cells | NA |
| AD Aβ-induced AD rat | Rat brain-derived NSCs with designer self-assemble peptide | Increased survival and differentiation of the grafted cells, enhanced neuroprotection, anti-neuroinflammatory and paracrine action | Improved behavior recovery |
| AD 192lgG-saporin-induced AD rat | Rat fetal brain-derived NSCs with nerve growth factor nanoparticles | Decreased Aβ plaques and increased synaptic density and plasticity | Improved cognitive, learning and memory, no change in anxiety level |
| AD 3x and Thy1-APP transgenic mouse | Nephrin in modified human NSCs | Enhanced neuronal connectivity and metabolic activity | Fail to improve learning and memory |
| AD APP/PS1 transgenic mouse | Human brain-derived NSCs | No changes in brain-derived neurotrophic factor and no increase in synaptic density | |
| HD R62 transgenic mouse | Commercial human fetal brain-derived CNS-SCs | Decreased ubiquitin-positive aggregation, polyglutamine aggregation and striatal volume | Improved motor function, memory performance and survival rate |
| HD R62 transgenic mouse | C17.2 NSCs with trehalose | Increased oligodendrocytes and neurons | Improved locomotor recovery |
| SCi Weight drop on mouse | Commercial human fetal brain-derived CNS-SCs | Migration of NSCs to the injury sites | Improved hind limb performance |
| SCi Weight drop on primate Hemisphere of rat | Adult monkey NSCs | Anti-inflammation and anti-apoptosis | Re-myelination, neural regeneration and improved locomotor function |
| SCi Weight drop on rat | Rat fetal brain-derived NSCs with etanercept | Decreased oxidative damage, increased survival and differentiation of NSCs | Improved rear-limb function |
| SCi Hemisection of rat | Rat fetal brain-derived NSCs with edaravone | Improved axonal regeneration | No functional recovery |
| SCi Hemisection of rat | Rat brain-derived NSCs-modified by NT-3 and TrkC gene with gelatin sponge scaffold | Increased survival of axotomized neurons and axonal regeneration | Improved partial locomotor functional recovery |
| SCi Weight drop on mouse | Commercial human fetal brain-derived CNS-SCs | No neuronal lineage differentiation of donor cells | No functional recovery |
| Stroke MCAO in rat | iPS-CNS derived NSCs | Enhanced endogenous neurogenesis and angiogenesis and increased trophic factors | Improved functional recovery |
| Stroke MCAO in rat | Mouse fetal brain-derived NSCs and ESCs-derived vascular progenitor cells | Enhanced neurovascular recovery and neurotrophic factors and decreased infarct volume | Improved functional neurological deficits |
| Stroke MCAO in rat | Sliding fibers containing human brain-derived NSCs | Increased survival rate of administered NSCs and decreased microglial infiltration | NA |
| TBI CCI in mouse | Mouse brain-derived NSCs | Increased oligodendrocytes, decreased astroglial activation and microglial/macrophage accumulation | Delayed spatial learning deficits |
| TBI CCI in rat | Sodium hyaluronate collagen scaffold loaded with rat brain-derived NSCs and bFGF | Increased survival and differentiation of NSCs and enhanced functional synapse formation | Improved cognitive function recovery |
| Epilepsy Kainic acid-induced rat | Rat embryonic medial ganglionic eminence-derived NSCs | Increased GABAergic neurons and GDNF expression in hippocampal astrocytes | Reduced spontaneous recurrent motor seizures |
| CP UCAO plus hypoxia in rat | Rat fetal NSCs transfected with VEGF | Increased VEGF protein expression and decreased neuronal apoptosis | Improved spatial discrimination, learning, memory recall capabilities and locomotor function |
Table 2 (Continued)

| Disease target | Animal model | Transplanted cell source | Therapeutic mechanism | Outcome | Refs |
|----------------|--------------|--------------------------|-----------------------|---------|------|
| CP UCAO plus hypoxia in rat | Rat fetal NSCs transfected with VEGF | Increased VEGF protein expression and neuroprotection | Improved motor function | 104 |
| HIE UCAL in neonatal mouse | Mouse fetal brain-derived NSCs with mild hypothermia treatment | Increased survival rate of NSCs, decreased caspase-3, NF-κB and cerebral infarct volumes | Improved functional recovery | 109 |
| HIE UCAL in neonatal rat | Human fetal brain-derived NSCs with ginsenoside Rg1 | Enhanced latency of somatosensory evoked potentials and increased neurotrophic factor | Improved learning and memory behavior | 110 |
| HIE Unilateral carotid artery cutting in rat | Human embryonic NSCs | Decreased IL-1β expression, increased NF-κB translocation, reduced brain tissue loss and white matter injury | Alleviated sensorimotor disabilities, improved learning, memory, and cognitive functions | 111 |

Abbreviations: Aβ, amyloid beta; AD, alzheimer’s disease; ALS, amyotrophic lateral sclerosis; APP, amyloid precursor protein; CCI, controlled cortical impact; CNS-SCs, central nerve system stem cells; CP, cerebral palsy; C17.2 cells, a murine neural progenitor cell line; ESCs, embryonic stem cells; GDNF, glial cell-derived neurotrophic factor; HD, huntington’s disease; HIE, neonatal hypoxic-ischemic encephalopathy; IL-1β, interleukin-1β; iPSCs, induced pluripotent stem cells; MCAO, middle cerebral artery occlusion; MFTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, used as neurotoxins; NA, not available; NF-κB, nuclear factor-κB; NPCs, neural progenitor cells; NSCs, neural stem cells; 6-OHDA, 6-hydroxydopamine, used as neurotoxins; PD, parkinson’s disease; PS1, presenilin 1; Rag-5xfAD mice, an immune-deficient transgenic model exhibited several hallmarks of AD pathogenesis; SCI, spinal cord injury; SOD1, superoxide dismutase 1; TBI, traumatic brain injury; UCAL, unilateral carotid artery ligation; UCAO, unilateral carotid artery occlusion; VEGF, vascular endothelial growth factor.
iPSCs, thus enabling the acquisition of a large number of NSCs and promoting basic research on NSCs. However, the differentiation of pluripotent stem cells into NSCs with high purity usually requires a long time and is accompanied by safety issues, thus complicating the translation of this procedure into a clinical therapy. Somatic cell transdifferentiation, especially methods without a viral strategy or integration of exogenous genes such as chemical-, growth factor-, 3D culture- or microRNA-induced cell transdifferentiation, into NSCs avoids the previous shortcomings and provides a very attractive strategy for the mass production of NSCs for clinical application.

MSCs have great value in regenerative medicine because autologous MSCs are easily harvested and can be effectively induced into a variety of specialized cells, including neural cells. MSC-derived neural stem-like cells have been found to exhibit significant neuroprotective effects. In addition, MSCs release paracrine signals that enhance neuronal cell proliferation and the differentiation of human NSCs in vitro in co-culture systems, except for the direct transition of MSCs to neural stem-like cells. Moreover, MSCs are a type of immune cell, which can be applied to decrease immune rejection, prolong the survival time of grafts and treat immune dysregulation. Importantly, MSCs alone have been used in many clinical trials for the treatment of neurodevelopmental disorders. Co-transplantation of bone marrow MSCs and adult NSCs in a transgenic rat model of HD has been found to confer long-term behavioral benefits and to improve survival of the transplanted NSCs. Thus, it should be anticipated that MSC-derived NSC-based therapy with or without MSCs will be a major direction for the treatment of nerve diseases in the future (Figure 3).

Although NSC treatment has exhibited some success in a variety of animal disease models, many problems remain to be addressed before transition to clinical applications because of the substantial physiological differences between humans and animals. First, clinical treatments must abide by standardized protocols. Therefore, detailed and efficient standards must be established for therapeutic routines, including stem cell types, the time of transplantation and cell dosage. Purity of NSCs is the priority and needs to be addressed and approved, as contamination of other cells may cause unexpected side effects. The optimal transplantation time for NSCs should be evaluated for each type of acute or chronic disease. Along with others, we have found that even primary tissue-derived NSCs or NPCs can form a clot in vivo if transplanted at high density; thus, the density of transplanted NSCs must be precisely controlled to avoid secondary damages to the injected tissues. Therapeutic routines for NSC administration, including local injection via intracranial or intraspinal routes and systemic injection via intravenous or intrathecal routes, are highly dependent on the lesion site. Second, stem cells that are used as seeds must be verified as safe both in vitro and in vivo. To accomplish this, we suggest carrying out deep sequencing and checking tumor formation potency in mice for every lot of manufactured NSC products. Third, the poor survival rate and the modest treatment effects of NSCs in vivo are major problems that still remain to be solved. Furthermore, the underlying mechanisms of stem cell therapy are still unclear, and hence, additional studies are required. Further basic research in related areas may help resolve the above-mentioned issues. Finally, advanced imaging techniques are required to monitor the physiological state of transplanted NSCs in vivo to exclude tumorigenicity and other pitfalls.

**Conflict of Interest**

The authors declare no conflict of interest.
### Table 3 Clinical trials for neural stem cell transplantation

| Conditions | Transplanted cells | Status/intervening results | Phase | Location | Start year |
|------------|--------------------|---------------------------|-------|----------|------------|
| ALS        | Spinal cord-derived NSCs | Safe with unilateral and bilateral intraspinal lumbar microinjection | Phase I | United States | 2011 |
| ALS        | Spinal cord-derived NSCs | No study results | Phase II | United States | 2012 |
| ALS        | Fetal brain-derived NSCs | Improved tibialis anterior | Phase I | Italy | 2012 |
| ALS        | CNS10-NPC-GDNF | Recruiting | Phase I | United States | 2016 |
| PD         | Parthenogenetic stem cell-derived NSCs | Recruiting | Phase I | Australia | 2015 |
| SCI        | ESCs-derived NPCs | Recruiting | Phase I/II | China | 2017 |
| SCI        | Fetal brain-derived NSCs | Invitation | Phase I/II | China | 2017 |
| SCI        | MSCs-derived NPCs | Active, not recruiting | Phase I | United States | 2013 |
| SCI        | MSCs-derived NSCs | Active, not tolerating | Phase I/II | Korea | 2005 |
| SCI        | Spinal cord-derived NSCs | Recruiting | Phase I | United States | 2013 |
| SCI        | CNS stem cells | Terminated, no study results | Phase II | United States, Canada | 2014 |
| SCI        | NSCs combined with Scaffold | Recruiting | Phase I/II | China | 2016 |
| SCI        | CNS stem cells | No study results | Phase I/II | Canada, Switzerland | 2011 |
| Stroke     | CTX0E03 | Improved neurological function with no adverse events | Phase I | United Kingdom | 2010 |
| Stroke     | CTX0E03 | Active, not recruiting | Phase II | United Kingdom | 2014 |
| CP         | Fetal brain-derived NPCs | Improvement of functional development and no delayed complications | NA | China | 2005 |
| CP         | Fetal brain-derived NSCs | Improvement with varying degrees and no severe adverse reactions | NA | China | 2005 |
| CP         | Bone marrow MSCs-derived NSCs | Optimal improvement in motor function | NA | China | 2010 |
| CP         | NSCs | Active, not recruiting | NA | China | 2016 |
| HIE        | NPCs with paracrine factors from MSCs | Recruiting | NA | China | 2014 |
| MD         | CNS stem cells | No study results | Phase I/II | United States | 2012 |
| LLI        | CTX0E03 | Active, not recruiting | Phase I | United Kingdom | 2013 |
| Glioma     | NSCs expressing E. Coli CD | No study results | Phase I | United States | 2010 |
| Glioma     | NSCs expressing E. Coli CD | Recruiting | Phase I | United States | 2013 |
| Glioma     | NSCs expressing Carboxylesterase | Recruiting | Phase I | United States | 2014 |
| Glioma     | NSCs loaded with oncolytic adenovirus | Recruiting | Phase I | United States | 2017 |
| GBM        | NPCs | Active, not recruiting | Phase I | United States | 2011 |
| GBM        | NSCs | Terminated, no study results | Phase III | United States | 2007 |

Abbreviations: ALS, amyotrophic lateral sclerosis; CNS10-NPC-GDNF, human neural progenitor cells secreting glial cell line-derived neurotrophic factor; CNS, central nerve system; CP, cerebral palsy; CTX0E03, immortalized human neural stem cell line; ESCs, embryonic stem cells; GBM, glioblastoma; HIE, neonatal hypoxic-ischemic encephalopathy; IBM, intraparenchymal brain metastases; LLI, lower limb ischemia; MD, macular degeneration; MS, multiple sclerosis; MSCs, mesenchymal stem cells; NPCs, neural progenitor cells; NSCs, neural stem cells; NSPCs, neural stem/progenitor cells; PD, Parkinson’s disease; SCI, spinal cord injury.

### Acknowledgements
This work was supported by the Shanghai Rising-Star Program (16QA1402800) and the Technological Innovation Program from Shanghai Jiao Tong University School of Medicine (16XJ11001).

### Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

1. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992; 255: 1707–1710.
2. Morshead CM, Reynolds BA, Craig CG, McBurney MW, Staines WA, Morassutti D et al. Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. Neuron 1994; 13: 1071–1082.
3. Weiss S, Dunne C, Hewson J, Wohl C, Wheatley M, Peterson AC et al. Isolation and characterization of neural stem cells from the adult human olfactory bulb. Nat Neurosci 2000; 3: 729–739.
4. Ferrari D, BINDA E, De Filippis L, Vescovi AL. Isolation of neural stem cells from neural tissues using the neurosphere technique. Curr Protoc Stem Cell Biol 2010; 15: 2D.6.1–2D.6.18.
5. Azari H, Rahman M, Sharififar S, Reynolds BA. Isolation and expansion of the adult mouse neural stem cells using the neurosphere assay. J Vis Exp 2010; 45: e2383.
6. Mothe A, Tator CH. Isolation of neural stem/progenitor cells from the periventricular region of the adult rat and human spinal cord. J Vis Exp 2015; 99: e52732.
7. Gritti A, Bonfanti L, Doetsch F, Caillé I, Alvarez-Buylla A, Lim DA et al. Multipotent neural stem cells reside into the rostral extension and olfactory bulb of adult rodents. J Neurosci 2002; 22: 437–445.
8. Pagano SF, Impagnatiello F, Greli M, Cova L, Grioni E, Onofri M et al. Isolation and characterization of neural stem cells from the adult human olfactory bulb. Nat Neurosci 2005; 8: 723–729.
9. Guo W, Patritz NE, Joe BM, Zhao X. Isolation of multipotent neural stem or progenitor cells from both the dentate gyrus and subventricular zone of a single adult mouse. Nat Protoc 2012; 7: 2005–2012.
10. Belenguer G, Domingo-Muñias A, Ferron SR, Morante-Roldán JM, Farinas I. Isolation, culture and analysis of adult subependymal neural stem cells. Differentiation 2016; 91: 28–41.
11. Koch P, Optiz T, Steinbeck JA, Ladewig J, Brustle O. A rosette-type, self-renewing human ES cell-derived neural stem cell with potential for in vitro instruction and synaptic integration. Proc Natl Acad Sci USA 2009; 106: 3225–3230.
12. Zhang SC, Wang D, Morgan ID, Brustle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001; 19: 1129–1133.
13. Kozich OA, Hamilton RS, Mallon BS. Standardized generation and differentiation of neural precursors from human pluripotent stem cells. Stem Cell Rev and Rep 2013; 9: 531–536.
14. Meneihrini V, Frati G, Sala D, De Ciccio S, Luciani M, Cavazzini C et al. Generation of human induced pluripotent stem cell-derived bona fide neural stem cells for ex vivo gene therapy of metachromatic leukodystrophy. Stem Cells Transl Med 2017; 6: 352–368.
16. Elizabetz Y, Studer L. Human ESC-derived neural rosettes and neural stem cell progression. Cold Spring Harb Symp Quant Biol 2008; 73: 377–387.

17. Wilson PG, Stice SS. Development and differentiation of neural rosettes derived from human embryonic stem cells. Stem Cell Rev 2006; 2: 67–77.

18. Elizabetz Y, Panagiotakos G, Al Shamy G, Qiu B, Zhao J, Guan W et al. Human neural stem cells reveal a functionally distinct early neural stem cell stage. Genes Dev 2008; 22: 152–165.

19. Daadi MM, Maag AL, Steinberg GK. Adherent self-renewal human embryonic stem cell-derived neural stem cell line: functional engraftment in experimental stroke model. PLoS One 2012; 7: e45005.

20. Banda E, Grabel L. Directed differentiation of human embryonic stem cells into neural progenitors. Methods Mol Biol 2013; 1307: 289–298.

21. Wen Y, Jin S. Production of neural stem cells from human pluripotent stem cells. Cell Stem Cell 2014; 15: 1–9.

22. Selman K, Kafatos FC. Transdifferentiation in the labial gland of silk moths: is DNA required for cellular metamorphosis? Cold Spring Harb Symp Quant Biol 1974; 39: 115–123.

23. Liu X, Zhu H, Sun X, Zuo F, Lei J, Wang Z et al. Human neural stem cell transplants improve motor function in a rat model of Huntington’s disease. Stem Cell Res Ther 2014; 5: 77–87.

24. Feng N, Han Q, Li J, Wang S, Li H, Yao X et al. Directed differentiation of human neural stem cells into amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 2014; 75: 363–373.

25. Mazzini L, Gelati M, Profico DC, Sgarzavici G, Proietti Pensi M, Muzi G et al. Human neural stem cell transplants improve motor function in a primate model of Parkinson’s disease. J Neurosci 2006; 26: 1247–1251.

26. Fujita H, Kusano H, Jin X, Liu J, Wang B et al. Towards a human neural stem cell transplant: the development of a first-in-human trial. Cell Stem Cell 2016; 28: 41–45.

27. Yan T et al. Derivation and therapeutic application of NSCs and pNSCs in brain diseases. Cell Death and Disease 2014; 5: e1127.
12

Derivation and therapeutic application of NSCs

Y Tang et al.

76. Ryu JK, Kim J, Cho SJ, Hatori K, Nagai A, Choi HB et al. Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis 2004; 16: 68–77.

77. Schneider RC, Thompson JM, Bebin J. The syndrome of acute central cerebral spinal cord injury. J Neurol Neurosurg Psychiatry 1958; 21: 216–227.

78. Salazar DL, Umeda N, Hamers F, Mischke JJ, Anderson AJ. Human neural stem cells differentiate and promote locomotor recovery in an early chronic spinal cord injury NOD-scid mouse model. PLoS ONE 2010; 5: e12272.

79. Nemati SN, Jabbari B, Hajnazarov M, Zareh Meydani N, Azizi H, Hemmée K et al. Transplantation of adult somatic neural stem cells into a contusion spinal cord injury model in the thalamus mouse monkey. Cell J 2014; 16: 113–120.

80. Wang L, Wei FX, Chen JS, Ping SN, Li QZ, Chen NN et al. Early administration of tumor necrosis factor-alpha antagonist promotes survival of transplanted neural stem cells and axon myelination after spinal cord injury in rats. Brain Res 2014; 1575: 87–100.

81. Song YY, Peng CG, Ye XB. Combination of edaravone and neural stem cell transplantation repairs injured spinal cord in rats. Genet Mol Res 2014; 13: 19136–19143.

82. Zhao Y, Zuo Y, Wang XL, Huo HJ, Jiang JM, Yan HB et al. Effect of neural stem cell transplantation combined with erythropoietin injection on axon regeneration in adult rats with transsected spinal cord injury. Genet Mol Res 2015; 14: 17799–17808.

83. et al. Neural stem cell and Schwann cell-loaded biodegradable polymer scaffolds support axonal regeneration in the transplanted spinal cord. Tissue Eng Part A 2009; 15: 1797–1805.

84. Du BL, Zeng X, Ma YH, Lai BQ, Wang JM, Ling EA et al. Graft of the gelatin sponge scaffold containing genetically-modified neural stem cells promotes cell differentiation, axon regeneration, and functional recovery in rat spinal cord transection. J Biomed Mater Res A 2010; 103: 1533–1545.

85. Anderson AJ, Ppti KM, Hooshmand MJ, Nishi RA, Cummings BJ et al. Preclinical efficacy of human neural stem cells in neonatal cerebral palsy rats. Stem Cell Res 2018; 26: 327–339.

86. Shin JC, Kim KN, Yang YS, Kim YJ, Lee H et al. Clinical trial of fetal human brain-derived neural stem/progenitor cell transplantation in patients with traumatic cervical spinal cord injury. Neural Plast 2015; 2015: 630932.

87. Dimagl U, Iadecola C, Moskowitz MA. Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 1999; 22: 391–397.

88. Diringer MN. Intracerebral hemorrhage: pathophysiology and management. Crit Care Med 1993; 21: 1591–1603.

89. Chau MJ, Deveau TC, Song M, Gu X, Chen D, Wei L. iPSC Transplantation increases regeneration and functional recovery after ischemic stroke in neonatal rats. Stem Cells Dev 2015; 24: 1947–1955.

90. Lee HJ, Kim KS, Kim EJ, Choi HB, Lee KH, Park IH et al. Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke model. Stem Cells 2007; 25: 1204–1212.

91. Li J, Tang Y, Wang Y, Tang R, Jiang W, Yang YG et al. Neurovascular recovery via co-transplanted neural progenitors and stem cells following ischemic stroke in rat. Stem Cell Rev 2014; 3: 101–114.

92. Lee S, Yun S, Park KI, Jiang JH. Sliding fibrin: sidable, injectable, and gel-like electrospun nanofibers as versatile cell carriers. ACS Nano 2016; 10: 3282–3294.

93. Minnerup J, Kim JB, Schmidt A, Diederich K, Bauer H, Schilling M et al. Effects of neural progenitor cells on somatosensory recovery and regeneration mechanisms after photothermal stroke. Stroke 2011; 42: 1757–1763.

94. Kalladka D, Sjendrin Pollock K, Haig C, McLean J, Smith W et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet 2016; 388: 787–796.

95. Engblom KG. Pathophysiology of traumatic brain injury. Br J Anaesth 2007; 99: 4–9.

96. Dixon KJ, Theus MH, Nelters CM, Mier J, Traveso LG, Yu TS et al. Endogenous neural stem/ progenitor cells stabilize the cortical microenvironment after traumatic brain injury. Neurotrauma 2015; 32: 753–784.

97. Koutsoudaki PN, Papastefanaki F, Stamatelakis A, Kourousli G, Xingi E, Mareschki K et al. Recapitulation of in vivo-like PARACINer signaling of human mesencephalic stem cells for functional neuronal differentiation of human neural stem cells in a 3D microfluidic system. Biomaterials 2015; 63: 177–188.

98. Croft AP, Przyborski SA. Mesencephalic stem cells expressing neural antigens instruct a neurogenic cell fate on neural stem cells. Exp Neurol 2009; 216: 329–341.

99. Wang Y, Tu W, Yie X, Aie L, Xiao GU et al. Mesencephalic stem cells regulate the proliferation and differentiation of neural stem cells through Notch signaling. Cell Biol Int 2009; 33: 1173–1179.

100. Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gnutti M, Mareschi K et al. Mesencephalic stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp Neurol 2016; 288: 116–124.

101. Pal R, Venkataramana NK, Bansal A, Barayaraj S, Jan M, Chandra RA et al. Ex vivo-expanded autologous bone marrow-derived mesencephalic stem cells in human spinal cord injury: a pilot clinical study. Cytotherapy 2009; 11: 897–911.

102. Rossignol J, Fink K, Davis K, Clerc S, Crane A, Matchynski J et al. Human neural stem cells prevent degeneration of striatal neurons in a rat model of Huntington’s disease. Stem Cells 2014; 32: 500–509.